-+ 0.00%
-+ 0.00%
-+ 0.00%

Antengene publishes preclinical study of ATG-037 plus selinexor in multiple myeloma in Cancer Gene Therapy

PUBT·09/14/2026 04:27:11
Listen to the news
Antengene publishes preclinical study of ATG-037 plus selinexor in multiple myeloma in Cancer Gene Therapy
  • Antengene disclosed preclinical multiple myeloma data on ATG-037 combined with selinexor in a newly published Cancer Gene Therapy paper.
  • Results have already been presented via publication, not slated for a future conference readout in the announcement.
  • The combination produced stronger tumor control than either drug alone in animal and lab studies.
  • Findings support a potential path to improve responses in resistant or refractory disease by restoring anti-tumor immune activity.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Antengene Corporation Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609140026PR_NEWS_USPR_____CN46711) on September 14, 2026, and is solely responsible for the information contained therein.